Document Type
Article
Publication Date
Spring 2020
ISSN
2163-1743
Publisher
American Bar Association
Language
en-US
Abstract
Over the past century, Congress has made the Food & Drug Administration (FDA) responsible for regulating the safety and efficacy of drugs and devices being deployed in the fight against the COVID-19 pandemic. The FDA’s regulatory infrastructure was built for public health threats and to combat manufacturers' misinformation about treatments.
This article spotlights the ways in which FDA has been adapting to a new challenge during the COVID-19 pandemic: combating misinformation emanating from within the executive branch.
Recommended Citation
Elizabeth McCuskey,
FDA In the Time of COVID-19
,
in
45
Administrative & Regulatory Law News
7
(2020).
Available at:
https://scholarship.law.bu.edu/faculty_scholarship/3675
